When four-month-old Melody Aggett developed what looked like an ordinary cold in April 2025, her parents expected a few days of snuffles. Then she struggled to breathe and feed. After hours without a wet nappy, Rachel-Elizabeth Hewitt and Kevin Aggett of Poole, Dorset, took her to hospital. An initial diagnosis of bronchiolitis did not hold. Further tests delivered news Rachel later described as a stabbing pain in the heart: Melody had acute myeloid leukaemia (AML), a rare, aggressive blood cancer that affects about 100 children and young people in the UK each year.

Treatment began at once. Melody received a platelet transfusion and was transferred to paediatric intensive care in Southampton. She spent about 30 days there, including roughly two weeks on a ventilator, and underwent two rounds of intensive chemotherapy plus repeated blood and platelet transfusions. Doctors called her case high-risk and complex. In August she was moved to Great Ormond Street Hospital for an urgent bone marrow transplant — the treatment her team described as the only realistic chance of a cure.

Through some of the hardest days, Melody kept smiling and giggling. “She’s an inspiration, because she’s smiled and giggled throughout, whereas I have cried continuously. She’s such a fighter even when feeling poorly,” her mother said. Staff and family treated that smile as more than a small mercy: it was proof she was still there. Rachel continued to breastfeed when she could. A heatable “Cuddles” teddy from Cancer Support UK later became another source of comfort on the ward.

What happened next was harder still. The transplant brought a brief window of hope, then complications, including graft-versus-host disease. The leukaemia returned. By late 2025 and early 2026, UK standard options had run out. Doctors searched internationally. Melody’s parents began raising funds for Revuforj, a menin-inhibitor approved in the United States but not funded on the NHS, at a cost of around £20,000 a month. A second transplant, if it became possible, could not be considered for years. The family said they could not give up while their daughter was still fighting.

Melody’s story is both a medical case and a warning. Infant AML can look, at first, like a lingering cold. Early tests changed the course of her care. The rest of the fight — ICU, chemotherapy, transplant, relapse, and a search for a drug the UK does not yet routinely provide — has left her parents holding tightly to the same thing that carried them through the first weeks: a baby who, even on the worst days, still knew how to smile.

Sources
The Mirror, 24 November 2025: “We thought baby had an ordinary cold – diagnosis didn’t feel real.”
Cancer Support UK / Devon Live / The Sun, November 2025: coverage of Melody’s diagnosis, ICU stay, and transplant.